July 2019- Volume 15, Issue 7

In this Issue

Business & Government Policy

Patent Docs: BIO International Convention wrap-up

Patent Docs: BIO International Convention wrap-up

Kevin Noonan, a partner with the law firm McDonnell Boehnen Hulbert & Berghoff LLP and founding author of the Patent Docs weblog, recaps the highlights of the latest annual BIO meeting

AbbVie makes $63B play for Allergan

AbbVie makes $63B play for Allergan

Proposed acquisition is said to be a ‘tranformative’ move for both companies

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Advancing biologics

Advancing biologics

FDA takes new step to help advance the transition of certain biological products

New mass spec for Thermo

New mass spec for Thermo

Thermo Fisher Scientific acquires Slovakian mass spec software firm HighChem

Preclinical

Immunotherapies vs. infections

Immunotherapies vs. infections

Breakthrough research identifies a potential vaccine against deadly fungus

The rodents shall remain

The rodents shall remain

Rats and mice expected to continue as most lucrative species for animal models

Stem-ulating research

Stem-ulating research

Two branches of stem cell research discover the impact on both diabetes and cardiac damage

Contract Services

Aldevron adds space

Aldevron adds space

Biologics manufacturer expands and names new business heads

Marking an anniversary

Marking an anniversary

BioAscent records successful first year as fully integrated discovery services CRO

Charles River cultivates change

Charles River cultivates change

Charles River constructs new collaborative science partnerships

Discovery

Gilead, Goldfinch take aim at kidney disease

Gilead, Goldfinch take aim at kidney disease

All told, the total deal value could reach over $2B if all milestones are met

Big agreements for Atomwise

Big agreements for Atomwise

Atomwise announces deals with Eli Lilly and Enamine

A better picture of how antibiotics kill

A better picture of how antibiotics kill

Machine learning reveals metabolic pathways disrupted by the drugs

Accelerating antibiotics

Accelerating antibiotics

Polyphor and the University of Zurich examine new class of drugs inhibiting the LPS transport pathway

Working to ‘develop tomorrow’s drugs’

Working to ‘develop tomorrow’s drugs’

GSK, University of California to establish new lab for genetic and CRISPR research

Research & Development

Amicus-Penn collaboration gains new life

Amicus-Penn collaboration gains new life

Partners have expanded their agreement to include new indications and new research programs

Collaboration center

Collaboration center

Platform will help to characterize biotherapeutic products

A need for diversity

A need for diversity

Study finds that over 75 percent of genomic data is of European origin

A banner day for modeling

A banner day for modeling

Q2 saw encouraging advances in disease modeling options

Meet the Mini-Brain

Meet the Mini-Brain

AxoSim licenses revolutionary Mini-Brain technology from Johns Hopkins

Diagnostics

Double duty for ingestible technology

Double duty for ingestible technology

Micro-bio-electronic device might be able to diagnose and treat GI problems

A stool test for cirrhosis

A stool test for cirrhosis

UC San Diego researchers analyze stool microbes to diagnose liver disease

ADDF commits $50M to early AD detection

ADDF commits $50M to early AD detection

Alzheimer’s Drug Discovery Foundation aims to fast-track digital tools for the disease

‘Liquid’ assets

‘Liquid’ assets

A look at a recent FDA decision and analyst forecasts in the field of liquid biopsy

Clinical Trials

If at first you don't succeed...

If at first you don't succeed...

Despite setback with IFX-1, InflaRx continues testing

Imago unveils IMG-7289

Imago unveils IMG-7289

Safety and efficacy data informs expansion of study into Phase 2b

Design in the cloud

Design in the cloud

Exploristics announces launch of KerusCloud 2.0

A faster track for flu vaccine

A faster track for flu vaccine

Novavax confirms accelerated approval pathway available for licensure of NanoFlu

A new network

A new network

National Kidney Foundation introduces its plan for an expansive kidney disease registry

Special Reports

Special Report on Drug Screening: Phenotypic finery

Special Report on Drug Screening: Phenotypic finery

Microscopy meets the molecular in the search for phenotypic impacts in drug screening

Feature

Focus Feature on Cancer Research News: Hitting the target

Focus Feature on Cancer Research News: Hitting the target

It’s never just been about killing or removing tumors; it’s about aiming at them accurately

Commentary

Guest Commentary: ACT clinical trials--The long road

Guest Commentary: ACT clinical trials--The long road

As excitement and investment related to adoptive cell transfer products increases, there are concerns and issues that need to be addressed in terms of long-term follow-up trials

Out of order: Inverted focus?

Out of order: Inverted focus?

Our microbiomes might adversely influence some therapeutics that we take, but does that mean that we should be altering the microbiome to compensate?

Editor's Focus

Editor’s focus: Off-target effect from inactives?

Editor’s focus: Off-target effect from inactives?

More information about adverse effects of so-called 'inactive' ingredients could be useful, but it also could just be a ton more information that we can't do much with once we have it
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue